Literature DB >> 10439688

[Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study].

P H Gaede1, P V Jepsen, H H Parving, O B Pedersen.   

Abstract

We carried out a randomized trial of stepwise intensive treatment or standard treatment of risk factors in patients with type 2 diabetes and microalbuminuria. Patients were allocated standard treatment (n = 80) or intensive treatment (n = 80). Intensive treatment was a stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria. The primary endpoint was development of nephropathy. Secondary endpoints were incidence or progression of diabetic retinopathy and neuropathy. Patients were followed for 3.8 years. The intensive group had significantly lower rates of progression to hephropathy (odds ratio 0.27 [95% CI 0.10-0.75]), progression of retinopathy (0.45 (0.21-0.95]), and progression of autonomic neuropathy (0.32 [0.12-0.78]). In conclusion, intensified multifactorial intervention in patients with type 2 diabetic mellitus and microalbuminuria has beneficial effects on long-term complications.

Entities:  

Mesh:

Year:  1999        PMID: 10439688

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  3 in total

Review 1.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

Review 2.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

Review 3.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.